Basilea announced Tuesday it will propose Anne Whitaker and Naseem Amin as latest members to its board of directors at the company’s upcoming general assembly.
The pharmaceutical company made the announcement alongside its annual results. Current board members Werner and Nicklasson have both decided not to seek re-election after 15 and 13 years of service, respectively, “to pass the baton to a new generation of directors,” according to a company statement.
Whitaker and Amin each bring extensive experience in the life sciences sector. Whitaker, a U.S. National, currently serves on the boards of Icon, Bespak, and QurAlis Corporation, where she is president. Amin, holding both British and U.S. Citizenship, is currently CEO of Orphalan.
Stephan Schindler will stand for re-election as chairman of the board of directors.
The board changes come as Basilea continues to navigate a competitive pharmaceutical landscape, and the appointments are expected to bring valuable expertise to the company’s strategic direction.
